

**Sterne Kessler  
Goldstein Fox**



Robert J. Kessler  
Edward A. Kessler  
Joseph A. Goldstein  
David K. N. Goldstein  
Robert W. Esmond  
Tia J. Daniels-Dunk  
Michael A. Cantale  
Michael B. Ray  
Robert E. Sukoff  
Eric K. Steffe  
Michael J. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Adorn  
Robert C. Melling  
Lawrence B. Budzinski  
Donald J. Reamont  
Michael J. Meyinger

Justin M. Kim  
Timothy J. Mearns  
Patrick E. Rasmussen  
Jeffery T. Hevey  
Heidi L. Knaus  
Crystal D. Davis  
Edward W. Yee  
Albert J. Ferris  
Donald R. Bandow  
Peter A. Jackman  
M. A. McFall  
Teresa L. Meder  
James S. Weaver  
Kenneth R. Patterson  
Vincent J. Caputo  
Albert J. Fasulo  
C. D. B. K. K. K. K.  
W. Russell Swinge

Thomas J. Kida  
Brian J. DeBorja  
John Lee Brashers  
Reginald J. Cowan  
Kimberly A. Reddy  
Theodore A. Wood  
Elizabeth J. Madies  
Bruce E. Chakke  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Chiller  
Kae Lynn Pringaman  
Jane Shersherovich  
Lawrence J. Lattin

Registered Patent Agents  
Karin R. Matkovic  
Andrea J. Matkovic  
Nancy J. Leff  
Joseph M. Cornfield  
Ann L. Summefeld  
Heather C. Carlson  
Betsy L. Longworth  
Matthew J. Dowd  
Aaron J. Schwartz  
Angela G. Ly  
Boris A. Matveenko  
Mah B. Tund

\*Admitted in Maryland  
\*Admitted in Virginia  
\*Admitted in Texas

March 11, 2002

WRITER'S DIRECT NUMBER:  
(202) 371-2609

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

MAR 13 2002

TECH CENTER 1600.2900

Group Art Unit 1647

Re: U.S. Utility Patent Application  
Appl. No. 09/722,495: Filed: November 28, 2000  
For: **Analog of Human basic Fibroblast Growth Factor**  
Inventors: Springer *et al.*  
Our Ref: 1503.0220002/JAG/THN

**RECEIVED**

MAR 12 2002

TC 1700

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 (17 sheets); and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
March 11, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,  
or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jorge A. Goldstein  
Attorney for Applicants  
Registration No. 29,021


Enclosures

P: USERS TARJAIN 1503 1503 0220002 pto IDS TRANS WPD

RECEIVED

MAR 13 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SPRINGER *et al*

Appl. No. 09/722,495

Filed: November 28, 2000

For: **Analog of Human basic  
Fibroblast Growth Factor**

Confirmation No. 5579

Art Unit: 1647

Examiner: Saoud, C.

Atty. Docket: 1503.0220002/JAG/TTIN

**Information Disclosure Statement**

**RECEIVED**

MAR 1 2 2002

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

**TC 1700**

MAR 1 3 2002

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted

herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Copies of the documents were cited by and submitted to the Office in Applicants' Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/826,210, filed April 5, 2001. Further to a telephonic conference on February 19, 2002, between Examiner Gary Koons and Tarja H. Naukkarinen of Sterne, Kessler, Goldstein & Fox, copies of the cited documents are not attached. If the Examiner does not have access to the copies of the cited documents, the Examiner is hereby invited to request the copies from the undersigned attorney of record.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jorge A. Goldstein  
Attorney for Applicants  
Registration No. 29,021

Date: \_\_\_\_\_

3/11/02

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600